(*) The transfer value used in the ratio calculations in the amount of USD 3,700,000 has been converted to TL by using the currency announced by the Central Bank on this date (i.e. 7.1324), the ratio will be recalculated on the transfer date once the value to be determined though counting becomes final.

(**) In terms of the Assets other than Inventory and Fixed Assets (Products, Marketing Authorizations regarding Products, Contracts, Operational Know-How and Domain Names), as these assets are "Intangible Assets" the account item "Net Value of Intangible Assets" indicated our Company's financial statements dated 30.9.2020, which have already been disclosed to the public, has been used for the calculation of the relevant ratio.

In our public disclosure dated 25 January 2016, we have announced in brief the decision that the hospital products business carried out by Baxter Hastane Ürünleri Sanayi ve Ticaret A.Ş. be terminated and as such, certain assets relating to the hospital products business be transferred to our subsidiary EİP Eczacıbaşı İlaç Pazarlama A.Ş. ("EİP") and a distribution agreement be signed between EİP and the Baxter group for the distribution of the hospital products by EİP.

In the Board of Directors of our subsidiary, EİP, convened today, the following was decided;

The exclusivity of the distribution Agreement signed with Baxter group on 2016 has ended on 2021 and Baxter Group has conveyed its intention to handle the relevant business internally. In light of the recent developments, especially in terms of the Covid-19 pandemic and our expectations of the sectors evolvement, Baxter's intention and other strategic options have been analysed and, as a result of which, it was decided that an Asset Sale and Purchase Agreement be signed between EİP and Baxter Turkey Renal Hizmetler A.Ş. ("Baxter Türkiye") in relation to the termination of EİP's distribution of hospital products business and transfer of assets in relation to the hospital products to Baxter Türkiye.

As per the relevant Asset Sale and Purchase Agreement Baxter Türkiye shall pay to EİP:

- In return for the assets other than inventory and fixed assets in relation to the hospital products business: USD 3.7 million + VAT on the 3rd of May which is the business day immediately following the 1st of May, defined as the transfer date ("Transfer Date"),

- In return for the inventory and fixed assets in relation to the hospital products business: the amount to be determined in TL by way of counting immediately prior to the Transfer Date and to be converted to USD based on the Central Bank's USD/TL currency rate applicable on the counting date, within 180 days following the transfer date,

- An additional amount related to the performance, based on the net sales generated by the relevant business in the year 2021 to be capped at USD 550,000, until 31 January 2022.

Contracts of the employees employed within the business subject to transfer will also be transferred to Baxter Türkiye together with their rights and obligations effective as of the Transfer Date.

An application shall be made to the Competition Authority for its approval to the transfer transaction and all issues that become final during the process will be shared with the public accordingly.

This statement has been translated into English for informational purposes. In case of a discrepancy between the Turkish and the English versions of this disclosure statement, the Turkish version shall prevail.